On this page
Miconazole Nitrate
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Azole Antifungal [EPC] | EPC | All 44 members |
| Azoles [CS] | CS | All 44 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 073508-001 | MICONAZOLE NITRATE | SUPPOSITORY | MICONAZOLE NITRATE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 15 | Manufacturing (CMC) | Approved | July 9, 2002 | — |
| Supplement | 14 | Manufacturing (CMC) | Approved | January 8, 2002 | — |
| Supplement | 13 | Manufacturing (CMC) | Approved | December 29, 2000 | — |
| Supplement | 12 | Manufacturing (CMC) | Approved | January 9, 1998 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | October 11, 1996 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | July 24, 1996 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | July 24, 1996 | — |
| Supplement | 5 | Manufacturing (CMC) | Approved | July 24, 1996 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | July 24, 1996 | — |
| Supplement | 8 | Manufacturing (CMC) | Approved | June 28, 1996 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | May 15, 1995 | — |
| Supplement | 1 | Manufacturing (CMC) | Approved | January 30, 1995 | — |
| Original application | 1 | Approved | November 19, 1993 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20201021). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Miconazole Nitrate Vaginal Suppositories USP, 200 mg are indicated for the local treatment of vulvovaginal candidiasis (moniliasis). Effectiveness in pregnancy has not been established. As miconazole nitrate is effective only for candidal vulvovaginitis, the diagnosis should be confirmed by KOH smear and/or cultures. Other pathogens commonly associated with vulvovaginitis ( Trichomonas and Haemophilus vaginalis [Gardnerella] ) should be ruled out by appropriate laboratory methods.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Miconazole Nitrate Vaginal Suppositories USP, 200 mg: One suppository (miconazole nitrate, 200 mg) is inserted intravaginally once daily at bedtime for three consecutive days. Before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or cultures to rule out other pathogens.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Patients known to be hypersensitive to this drug.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS During clinical studies with Miconazole Nitrate Vaginal Suppositories USP, 200 mg, 301 patients were treated. The incidence of vulvovaginal burning, itching or irritation was 2%. Complaints of cramping (2%) and headaches (1 . 3%) were also reported. Other complaints (hives, skin rash) occurred with less than a 0 . 5% incidence. The therapy-related dropout rate was 0 . 3%. To report SUSPECTED ADVERSE EVENTS, contact Teva Pharmaceuticals USA, Inc., at 1-888-838-2872 or FDA at 1-800-FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions.
Description
openFDA Drug LabelingDESCRIPTION Miconazole Nitrate Vaginal Suppositories USP, 200 mg are white to off-white suppositories, each containing the antifungal agent, miconazole nitrate, USP 1-[2,4-Dichloro-β-[(2,4- dichlorobenzyl)oxy] phenethyl]-imidazole mononitrate, 200 mg, in a hydrogenated vegetable oil base. The molecular formula is C 18 H 14 Cl 4 N 2 O•HNO 3 ; the molecular weight is 479.14 and the structural formula may be represented as follows: 009711be-figure-01
Overdosage
openFDA Drug LabelingOVERDOSAGE Overdosage of miconazole nitrate in humans has not been reported to date. In mice, rats, guinea pigs and dogs, the oral LD 50 values were found to be 578 . 1, greater than 640, 275 . 9 and greater than 160 mg/kg, respectively.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Miconazole Nitrate Vaginal Suppositories USP, 200 mg are available as elliptically shaped white to off-white suppositories in packages of three with a vaginal applicator NDC 0472-1738-03. Store at controlled room temperature 15° to 30°C (59° to 86°F). Manufactured for: Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054 Rev. A 7/2020
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: MICONAZOLE NITRATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0472-1738-03 | 0472-1738 | Actavis Pharma, Inc. | 3 SUPPOSITORY in 1 CARTON (0472-1738-03) | January 18, 1995 |
| 11014-0343-1 | 11014-0343 | Catalent Pharma Solutions, LLC | 1 BAG in 1 CONTAINER (11014-0343-1) / 2000 SUPPOSITORY in 1 BAG | December 10, 2009 |
| 65655-0013-1 | 65655-0013 | Swiss Caps AG | 2 BAG in 1 CARTON (65655-0013-1) / 1200 SUPPOSITORY in 1 BAG | June 29, 2001 |
| 65655-0014-1 | 65655-0014 | Swiss Caps AG | 2 BAG in 1 CARTON (65655-0014-1) / 1200 SUPPOSITORY in 1 BAG | April 16, 1996 |
| 0472-1738 | 0472-1738 | Actavis Pharma, Inc. | — | January 18, 1995 |
| 11014-0343 | 11014-0343 | Catalent Pharma Solutions, LLC | — | December 10, 2009 |
| 65655-0013 | 65655-0013 | Swiss Caps AG | — | June 29, 2001 |
| 65655-0014 | 65655-0014 | Swiss Caps AG | — | April 16, 1996 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.